Abivax S.A. (ABVX) shares plummeted 6.11% during Tuesday's intraday trading session, reflecting investor concerns over the company's widening third-quarter loss.
The biopharmaceutical firm reported a Q3 loss of 2.10 euros per diluted share, significantly higher than the 0.87 euro loss recorded a year earlier. While operating income rose to 2 million euros from 1.3 million euros, the increased losses overshadowed this improvement, triggering a sell-off.
Abivax emphasized its strong cash position (589.7 million euros), sufficient to fund operations through Q4 2027, but the market's focus remained on the deteriorating bottom line.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments